Crystagen
Also known as: Glu-Asp-Pro, EDP
Key Facts: Crystagen
- Category
- Bioregulators
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical research, approved in Russia as supplement
- Administration
- Oral capsules or sublingual
- Typical Dose
- 10-20 mg daily
- Frequency
- Once or twice daily
- Evidence Level
- Preclinical
- Duration
- 10-30 day cycles
What to Expect
A tripeptide bioregulator supporting immune system function. Demonstrates age-associated immunoprotective properties in spleen tissue. Part of the Khavinson synthesized peptide series.
Mechanism of Action
Crystagen possesses immunoprotective properties, particularly in splenic tissue. It modulates immune cell function and gene expression patterns related to immune response, helping maintain healthy immune function during aging.
Research Summary
Studies show Crystagen has different age-associated immunoprotecting properties in the spleen compared to other peptides like vilon, thymogen, and R-1. Research demonstrates tissue-specific regulatory effects on immune cells.
Dosing Information
Typical Dosingⓘ
Community experience
10-20 mg daily
10-20 mg daily
Once or twice daily
Immune system bioregulator. Part of Khavinson's synthesized peptides.
Research Dosingⓘ
Scientific studies
Doses from bioregulator supplement protocols
Doses from Studies
10-20 mg daily
Duration
10-30 day cycles
Administration
Oral capsules or sublingual
Timing & Administration
Best Time to Take
Morning on empty stomach
Once or twice daily
Food Recommendation
Take on empty stomach
Why This Timing?
Peptide bioregulators typically taken fasted for optimal absorption
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Limited safety data outside Russia
- ●Not FDA approved
References
Related Peptides
Peptides commonly compared with Crystagen or used in similar applications.
Thymalin
Clinical TrialsA thymic peptide complex used in Russia for immune enhancement and anti-aging. Part of Professor Khavinson's bioregulator peptide research.
BioregulatorsVentfort
PreclinicalA peptide bioregulator targeting vascular tissue and blood vessels. Derived from blood vessel extracts, it supports healthy vascular function and vessel wall integrity. Part of the Khavinson bioregulator family.
BioregulatorsEpithalon
Clinical TrialsA tetrapeptide studied for its effects on telomerase activation and potential anti-aging properties. Based on research by Professor Vladimir Khavinson.
BioregulatorsVilon
PreclinicalA synthetic dipeptide bioregulator targeting thymic function. Part of Khavinson's peptide bioregulator research for immune and anti-aging effects.
BioregulatorsLivagen
PreclinicalA tetrapeptide bioregulator (Lys-Glu-Asp-Ala) developed by Khavinson that modulates chromatin structure and gene expression. Research shows it can decondense heterochromatin and activate ribosomal genes, potentially restoring more youthful gene expression patterns in aging cells.
BioregulatorsOvagen
PreclinicalA tripeptide bioregulator (Glu-Asp-Leu) targeting liver and gastrointestinal tissue. Derived from liver tissue extracts, Ovagen modulates gene expression related to detoxification, antioxidant defense, and hepatocellular repair.
BioregulatorsWant updates on Crystagen research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.